Citation Impact
Citing Papers
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
2014 Standout
MYC Drives Pten/Trp53 -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
2015
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
2016
JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2013
The role of IL-6 in the radiation response of prostate cancer
2013
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
2016
Head and neck squamous cell carcinoma
2020 Standout
Long QT Syndrome: Genetics and Future Perspective
2019
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Inflammation and cancer: advances and new agents
2015
Myeloid-derived suppressor cells coming of age
2018 Standout
Proteasome inhibitors in cancer therapy
2017
Targeting Interleukin-6 Signaling in Clinic
2019
Cytokines in CAR T Cell–Associated Neurotoxicity
2020
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
2015
Regulation and Functions of the ER-Associated Nrf1 Transcription Factor
2022 StandoutNobel
Interleukin-6 signaling pathway in targeted therapy for cancer
2012
Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009
2010 Standout
Ranolazine Shortens Repolarization in Patients with Sustained Inward Sodium Current Due to Type‐3 Long‐QT Syndrome
2008
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
The biology and function of fibroblasts in cancer
2016 Standout
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
2015
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
2009 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Discovery and characterization of olokizumab
2014
Ventricular Arrhythmias in the Absence of Structural Heart Disease
2012
The genetic basis of long QT and short QT syndromes: A mutation update
2009
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
IL-6 as a keystone cytokine in health and disease
2015 Standout
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
Long-QT Syndrome
2008
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Emerging strategies for cancer immunoprevention
2015
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
2020
Pyroptosis: mechanisms and diseases
2021 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up
2010
European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support
2010 Standout
How were new medicines discovered?
2011 Standout
Interleukin-6: An angiogenic target in solid tumours
2013
Contraceptive Hormone Use and Cardiovascular Disease
2009
The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
2013
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary
2008
The IL-6 feed-forward loop: A driver of tumorigenesis
2014
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
2017
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Long QT Syndrome in Children in the Era of Implantable Defibrillators
2007
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases
2014
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
2013
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
2018
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
2020 Standout
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
2008 Standout
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
2013
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture
2011 StandoutNobel
Resistance to proteasome inhibitors and other targeted therapies in myeloma
2018
Cytokine Storm
2020 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
2015
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy
2008
Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells
2019
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
2014
Overview of Castleman disease
2020
Genetic Characteristics of Children and Adolescents With Long-QT Syndrome Diagnosed by School-Based Electrocardiographic Screening Programs
2013
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
2013
Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?
2010
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
2019
2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2012
Works of Ming Qi being referenced
A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
2013
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
2019
Clinical Course and Risk Stratification of Patients Affected with the Jervell and Lange‐Nielsen Syndrome
2006
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
2012
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
2016
Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial
2005
Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome
2010
Risk of Fatal Arrhythmic Events in Long QT Syndrome Patients After Syncope
2010
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
2011
Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome
2011
Dose selection of siltuximab for multicentric Castleman’s disease
2015
Long QT Syndrome and Pregnancy
2007
Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome
2006
Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
2012
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
2015
Long-QT Syndrome After Age 40
2008
Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,
2011
Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome
2008